News
Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...
Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback